A detailed history of Rhenman & Partners Asset Management Ab transactions in Essa Pharma Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 804,649 shares of EPIX stock, worth $1.41 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
804,649
Previous 806,054 0.17%
Holding current value
$1.41 Million
Previous $4.24 Million 15.03%
% of portfolio
0.41%
Previous 0.42%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$4.45 - $7.1 $6,252 - $9,975
-1,405 Reduced 0.17%
804,649 $4.88 Million
Q2 2024

Aug 13, 2024

SELL
$4.63 - $8.42 $489,696 - $890,549
-105,766 Reduced 11.6%
806,054 $4.24 Million
Q1 2024

May 14, 2024

BUY
$6.17 - $10.65 $3.43 Million - $5.91 Million
555,320 Added 155.77%
911,820 $7.74 Million
Q3 2023

Nov 13, 2023

BUY
$2.65 - $3.31 $324,625 - $405,475
122,500 Added 52.35%
356,500 $1.1 Million
Q3 2023

Nov 09, 2023

SELL
$2.65 - $3.31 $324,625 - $405,475
-122,500 Reduced 34.36%
234,000 $723,000
Q1 2023

May 11, 2023

SELL
$2.56 - $3.55 $47,360 - $65,675
-18,500 Reduced 4.93%
356,500 $1.06 Million
Q2 2022

Aug 12, 2022

SELL
$3.15 - $7.94 $113,157 - $285,228
-35,923 Reduced 8.74%
375,000 $1.18 Million
Q1 2022

May 13, 2022

SELL
$6.18 - $14.44 $56,095 - $131,071
-9,077 Reduced 2.16%
410,923 $2.54 Million
Q4 2021

Feb 11, 2022

SELL
$7.8 - $14.38 $1.4 Million - $2.59 Million
-180,000 Reduced 30.0%
420,000 $5.93 Million
Q3 2021

Nov 12, 2021

BUY
$7.76 - $29.37 $2.64 Million - $9.99 Million
340,000 Added 130.77%
600,000 $4.8 Million
Q1 2021

May 14, 2021

BUY
$11.61 - $32.08 $1.2 Million - $3.31 Million
103,300 Added 65.92%
260,000 $7.55 Million
Q4 2020

Jan 19, 2021

BUY
$5.47 - $12.1 $857,149 - $1.9 Million
156,700 New
156,700 $1.87 Million

Others Institutions Holding EPIX

About ESSA Pharma Inc.


  • Ticker EPIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,073,100
  • Market Cap $77.1M
  • Description
  • ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...
More about EPIX
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.